Atezolizumab - Latest Advances

Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series.

Journal: Renal failure

Published: October 14, 2025

Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis.

Journal: Human vaccines & immunotherapeutics

Published: October 13, 2025

Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with small cell lung cancer: A dramatic recovery after chemotherapy.

Journal: Internal medicine (Tokyo, Japan)

Published: October 01, 2025

Transarterial radioembolization challenges immunotherapy as first-line care for hepatocellular carcinoma with portal vein tumor thrombosis.

Journal: Diagnostic and interventional imaging

Published: September 30, 2025

Challenges of using bevacizumab for hepatocellular carcinoma: incidence of adverse effects and mitigation strategies.

Journal: Revista espanola de enfermedades digestivas

Published: September 29, 2025

Clinical features, treatments, and outcomes of atezolizumab-induced diabetes mellitus in cancer patients.

Journal: Journal of chemotherapy (Florence, Italy)

Published: September 22, 2025

Adverse Events of Immune Checkpoint Inhibitors in Cancer Patients with Comorbid Diabetes: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System Database (2011-2025).

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: September 19, 2025

Immunotherapy-Induced Hepatitis Mimicking Sclerosing Cholangitis in a Patient With Metastatic Triple-Negative Breast Cancer.

Journal: Cureus

Published: September 16, 2025

Cutaneous reaction to cancer treatment: Atezolizumab-induced lichen planus pemphigoides.

Journal: JAAD case reports

Published: September 08, 2025

ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 05, 2025

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

Journal: Internal medicine (Tokyo, Japan)

Published: September 03, 2025

Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Journal: Journal for immunotherapy of cancer

Published: August 31, 2025

Filters

Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series.

Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series.

Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis.

Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis.

Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with small cell lung cancer: A dramatic recovery after chemotherapy.

Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with small cell lung cancer: A dramatic recovery after chemotherapy.

Transarterial radioembolization challenges immunotherapy as first-line care for hepatocellular carcinoma with portal vein tumor thrombosis.

Transarterial radioembolization challenges immunotherapy as first-line care for hepatocellular carcinoma with portal vein tumor thrombosis.

Challenges of using bevacizumab for hepatocellular carcinoma: incidence of adverse effects and mitigation strategies.

Challenges of using bevacizumab for hepatocellular carcinoma: incidence of adverse effects and mitigation strategies.

Clinical features, treatments, and outcomes of atezolizumab-induced diabetes mellitus in cancer patients.

Clinical features, treatments, and outcomes of atezolizumab-induced diabetes mellitus in cancer patients.

Adverse Events of Immune Checkpoint Inhibitors in Cancer Patients with Comorbid Diabetes: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System Database (2011-2025).

Adverse Events of Immune Checkpoint Inhibitors in Cancer Patients with Comorbid Diabetes: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System Database (2011-2025).

Immunotherapy-Induced Hepatitis Mimicking Sclerosing Cholangitis in a Patient With Metastatic Triple-Negative Breast Cancer.

Immunotherapy-Induced Hepatitis Mimicking Sclerosing Cholangitis in a Patient With Metastatic Triple-Negative Breast Cancer.

Cutaneous reaction to cancer treatment: Atezolizumab-induced lichen planus pemphigoides.

Cutaneous reaction to cancer treatment: Atezolizumab-induced lichen planus pemphigoides.

ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC).

ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC).

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.